Education
About Us
Working with TipRanks
Follow Us
Moleculin Biotech (MBRX)
:MBRX
MBRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.25 - $3.65
Previous CloseN/A
Volume63.82K
Average Volume (3M)8.75M
Market Cap
$20.68M
Enterprise Value$1.83M
Total Cash (Recent Filing)$7.72M
Total Debt (Recent Filing)$450.00K
Price to Earnings (P/E)―
Beta1.84
Next Earnings
Aug 13, 2025EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.69
Shares Outstanding30,207,495
10 Day Avg. Volume4,086,187
30 Day Avg. Volume8,748,601
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-59.07
Enterprise Value/Ebitda-0.07
Forecast
1Y Price Target
$7.00Price Target Upside929.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Clinical Trial AdvancementsPositive FDA feedback brings annamycin one step closer to clinical evaluation in pediatric cancer patients.
Financial StrategyThe company was able to successfully complete two transactions under more favorable terms, including a warrant inducement transaction and a registered direct offering, which combined raised $9.3M.
Regulatory ProgressThe recent approval further expands the reach of the global approval study and bolsters enrollment efforts, which already includes clinical sites in the U.S., Europe, and the Middle East.
Bears Say
Capital RequirementsThe company needs to raise additional capital in the near-term which we factor in.
Stock PerformanceDespite the overall positive readout, MBRX shares are down ~20%, most likely related to the ongoing capital raising effort to support the P3 MIRACLE study.
Moleculin Biotech News
MBRX FAQ
What was Moleculin Biotech’s price range in the past 12 months?
Moleculin Biotech lowest stock price was $0.25 and its highest was $3.65 in the past 12 months.
What is Moleculin Biotech’s market cap?
Moleculin Biotech’s market cap is $20.68M.
When is Moleculin Biotech’s upcoming earnings report date?
Moleculin Biotech’s upcoming earnings report date is Aug 13, 2025 which is in 6 days.
How were Moleculin Biotech’s earnings last quarter?
Moleculin Biotech released its earnings results on May 14, 2025. The company reported -$0.69 earnings per share for the quarter, missing the consensus estimate of -$0.555 by -$0.135.
Is Moleculin Biotech overvalued?
According to Wall Street analysts Moleculin Biotech’s price is currently Undervalued.
Does Moleculin Biotech pay dividends?
Moleculin Biotech does not currently pay dividends.
What is Moleculin Biotech’s EPS estimate?
Moleculin Biotech’s EPS estimate is -0.4.
How many shares outstanding does Moleculin Biotech have?
Moleculin Biotech has 30,207,495 shares outstanding.
What happened to Moleculin Biotech’s price movement after its last earnings report?
Moleculin Biotech reported an EPS of -$0.69 in its last earnings report, missing expectations of -$0.555. Following the earnings report the stock price went down -7.477%.
Which hedge fund is a major shareholder of Moleculin Biotech?
Currently, no hedge funds are holding shares in MBRX
Company Description
Moleculin Biotech
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
MBRX Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented several positive developments, including the start of a pivotal Phase 3 trial, regulatory approvals, and promising preliminary data. However, financial constraints and potential regulatory hurdles in the EU were noted as significant challenges.View all MBRX earnings summariesMBRX Stock 12 Month Forecast
Average Price Target
$7.00
▲(929.41% Upside)
Technical Analysis
Ownership Overview
3.50% Insiders
0.17% Mutual Funds
<0.01% Other Institutional Investors
96.23% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---